Illumina, Inc. vs ProShares UltraPro QQQ ETF — how do they compare? Illumina, Inc. trades at $278.17 (market cap $39.95B), while ProShares UltraPro QQQ ETF trades at $81.28 (market cap $38.74B). The key difference: Illumina, Inc. and ProShares UltraPro QQQ ETF are close in size by market cap, and ProShares UltraPro QQQ ETF is more actively traded (65,384,797 versus 3,169,503). Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and ProShares UltraPro QQQ ETF for 24 Days on average.
| ILMN | TQQQ | |
|---|---|---|
Market Cap | $39.95B | $38.74B |
Volume | 3,169,503 | 65,384,797 |
Sector | Health | Leveraged / Inverse |
52-Week High | $293.69 | $87.22 |
52-Week Low | $91.00 | $37.89 |
Typical Hold Time | 83 Days | 24 Days |
Enterprise Value | $41.31B | — |
Signals from Pluang's Aura AI — not financial advice
ILMN trades at $264.40, down 1.25% on the day, but remains near its recent 52-week high of $278.99 (Defense World, 2026-10-01). The stock has surged 94.9% year-to-date (Zacks Investment Research, 2026-09-24), supported by strong earnings beats in recent quarters and a bullish technical trend. Fundamentals show a significant turnaround, with 2025 net income reaching $850 million after prior losses, though valuation ratios like a P/E of 49.36 are elevated. The pending inclusion in the S&P 500 (PRNewsWire, 2026-09-04) adds a positive catalyst.
The outlook is positive, driven by sequencing growth, AI integration in genomics, and improved profitability. However, risks include high valuation sensitivity, cost volatility, and competitive pressures in the life sciences sector. Analyst consensus is bullish with a 54% buy rating, but the average price target of $241 suggests limited near-term upside from current levels.
TQQQ trades at $80.22, down 4.04% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF's 3x leverage amplifies Nasdaq-100 moves, yet hidden costs like financing charges impact returns. Recent news highlights volatility risks and institutional position changes, while support sits at $78 and resistance at $83.
Outlook remains mixed: bullish technicals and AI-driven tech growth offer upside, but leverage decay and market volatility pose significant risks. Investors face amplified losses in downturns, warranting caution despite short-term momentum opportunities.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →